MetLife Investment Management LLC Decreases Stake in Supernus Pharmaceuticals, Inc. $SUPN

MetLife Investment Management LLC reduced its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 1.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,333 shares of the specialty pharmaceutical company’s stock after selling 489 shares during the period. MetLife Investment Management LLC’s holdings in Supernus Pharmaceuticals were worth $993,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Vident Advisory LLC raised its stake in Supernus Pharmaceuticals by 2.2% during the fourth quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company’s stock worth $520,000 after purchasing an additional 309 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Supernus Pharmaceuticals by 2.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,664 shares of the specialty pharmaceutical company’s stock worth $480,000 after purchasing an additional 350 shares during the period. Raiffeisen Bank International AG purchased a new position in Supernus Pharmaceuticals during the fourth quarter worth about $25,000. PNC Financial Services Group Inc. raised its stake in Supernus Pharmaceuticals by 4.7% during the first quarter. PNC Financial Services Group Inc. now owns 16,097 shares of the specialty pharmaceutical company’s stock worth $527,000 after purchasing an additional 726 shares during the period. Finally, Quantinno Capital Management LP raised its stake in Supernus Pharmaceuticals by 11.5% during the fourth quarter. Quantinno Capital Management LP now owns 8,401 shares of the specialty pharmaceutical company’s stock worth $304,000 after purchasing an additional 864 shares during the period.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $46.00 on Friday. The company’s 50 day simple moving average is $38.01 and its 200-day simple moving average is $34.14. The company has a market capitalization of $2.58 billion, a price-to-earnings ratio of 40.00 and a beta of 0.79. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $46.10.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Wall Street Zen raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 19th. Cantor Fitzgerald lifted their target price on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 6th. Finally, Piper Sandler lifted their target price on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a “neutral” rating in a research note on Friday, August 29th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Supernus Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $43.00.

Insiders Place Their Bets

In related news, CEO Jack A. Khattar sold 1,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $45.00, for a total value of $45,000.00. Following the completion of the transaction, the chief executive officer owned 1,071,459 shares in the company, valued at approximately $48,215,655. The trade was a 0.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Timothy C. Dec sold 11,780 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $44.49, for a total transaction of $524,092.20. Following the completion of the transaction, the chief financial officer owned 1,246 shares of the company’s stock, valued at $55,434.54. This trade represents a 90.43% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 179,606 shares of company stock worth $7,617,005. Insiders own 8.80% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.